Significant data demonstrate that Donanemab, an investigational drug, has the potential to reduce the development of mild cognitive decline. This treatment focuses on clearing amyloid deposits in https://deborahajng863874.blog5.net/92120892/nadecenemab-a-promising-novel-dementia-treatment